Pietro A. Canetta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pietro A. Canetta has a total of 948 co-authors. Here are the top co-authors by number of shared publications:
Gerald B. Appel
Division of Nephrology, Department of Medicine, Columbia University Medical Center, New York, USA
28 shared publicationsJai Radhakrishnan
Division of Nephrology, Department of Medicine, Columbia University Medical Center, New York, USA
23 shared publicationsAndrew S. Bomback
Division of Nephrology, Department of Medicine, Columbia University Medical Center, New York, USA
16 shared publications- Maddalena Marasa
Clinical Research Center for Rare Diseases “Aldo e Cele Daccò”, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy
11 shared publications - Ali G. Gharavi
Department of Medicine, Division of Nephrology, Columbia University College of Physicians and Surgeons, New York, New York, USA
10 shared publications - Andrew S. Bomback
Division of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, New York
9 shared publications
Latest Publications
- 7 August 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (11) , 1981-1994
Primary Glomerular Diseases in the Elderly
Key Points: Elderly onset primary glomerular diseases are characterized by decreased GFR and a higher comorbidity burden compared with younger adult subgroups. Histologic features of nephrosclerosis become more prevalent with advancing age. Excess morbidity, mortality and, possibly, underlying biologic differences, shape outcomes in elderly onset primary glomerular diseases. Background: Primary glomerular diseases (PGDs) are not uncommon in elderly patients, where age-related histologic changes, frailty, and multimorbidity overlap with disease-specific drivers of damage. Evidence on the impact of older age at onset on PGD presentation and outcomes remains heterogeneous. This retrospective multicenter study assessed the impact of older age at diagnosis on the clinical–histologic presentation, treatment, and outcome of PGDs. Methods: Adults with biopsy-proven minimal change disease, FSGS, membranous nephropathy, and IgA nephropathy/vasculitis with nephritis enrolled in Cure Glomerulonephropathy between 2014 and 2023 with available kidney function data were stratified by age at diagnosis into three age groups: young adults (18–39 years), middle-aged adults (40–64 years), and elderly patients (≥65 years). Clinical–histologic features and treatment patterns were compared across age groups, with a focus on elderly patients. Evaluated outcomes included all-cause mortality and a composite kidney outcome (>40% eGFR decline or kidney failure). Cox regression and Fine–Gray models were fitted to evaluate the impact of age on the composite kidney outcome. Results: Among 1562 adults, 211 were aged ≥65 years at diagnosis. Elderly patients exhibited a higher comorbidity burden and lower eGFR at enrollment (55 [34–75] versus 84 [50–115] in young adults and 65 [43–91] ml/min in middle-aged adults, P < 0.001). In 704 biopsies with an available Cure Glomerulopathy Pathology Classification, nephrosclerosis features—particularly arteriosclerosis—increased with advancing age, whereas disease-specific features were similar across age groups. Elderly patients more often received conservative or steroid-sparing regimens. A 5-year excess mortality of 7%–14% compared with young adults was observed in the elderly patients. In adjusted models, older age was independently protective for the composite kidney outcome (subdistribution hazard ratios 0.65–0.79). Conclusions: Aging adds comorbidity and histologic chronicity without altering PGDs phenotype; excess mortality and, possibly, underlying biologic differences shape outcomes in elderly onset PGDs.
- 7 August 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (11) , 1981-1994
Primary Glomerular Diseases in the Elderly
Key Points: Elderly onset primary glomerular diseases are characterized by decreased GFR and a higher comorbidity burden compared with younger adult subgroups. Histologic features of nephrosclerosis become more prevalent with advancing age. Excess morbidity, mortality and, possibly, underlying biologic differences, shape outcomes in elderly onset primary glomerular diseases. Background: Primary glomerular diseases (PGDs) are not uncommon in elderly patients, where age-related histologic changes, frailty, and multimorbidity overlap with disease-specific drivers of damage. Evidence on the impact of older age at onset on PGD presentation and outcomes remains heterogeneous. This retrospective multicenter study assessed the impact of older age at diagnosis on the clinical–histologic presentation, treatment, and outcome of PGDs. Methods: Adults with biopsy-proven minimal change disease, FSGS, membranous nephropathy, and IgA nephropathy/vasculitis with nephritis enrolled in Cure Glomerulonephropathy between 2014 and 2023 with available kidney function data were stratified by age at diagnosis into three age groups: young adults (18–39 years), middle-aged adults (40–64 years), and elderly patients (≥65 years). Clinical–histologic features and treatment patterns were compared across age groups, with a focus on elderly patients. Evaluated outcomes included all-cause mortality and a composite kidney outcome (>40% eGFR decline or kidney failure). Cox regression and Fine–Gray models were fitted to evaluate the impact of age on the composite kidney outcome. Results: Among 1562 adults, 211 were aged ≥65 years at diagnosis. Elderly patients exhibited a higher comorbidity burden and lower eGFR at enrollment (55 [34–75] versus 84 [50–115] in young adults and 65 [43–91] ml/min in middle-aged adults, P < 0.001). In 704 biopsies with an available Cure Glomerulopathy Pathology Classification, nephrosclerosis features—particularly arteriosclerosis—increased with advancing age, whereas disease-specific features were similar across age groups. Elderly patients more often received conservative or steroid-sparing regimens. A 5-year excess mortality of 7%–14% compared with young adults was observed in the elderly patients. In adjusted models, older age was independently protective for the composite kidney outcome (subdistribution hazard ratios 0.65–0.79). Conclusions: Aging adds comorbidity and histologic chronicity without altering PGDs phenotype; excess mortality and, possibly, underlying biologic differences shape outcomes in elderly onset PGDs.
- Open Access
- 20 July 2026
- Published by Elsevier in Kidney International Supplements
- Vol. 15 (1) , 14-23
Management of IgA nephropathy and the expanding role of immunomodulation
- 20 July 2026
- Published by Elsevier in Kidney International Supplements
- Vol. 15 (1) , 14-23
Open AccessManagement of IgA nephropathy and the expanding role of immunomodulation
- 26 June 2026
- Published by Elsevier in Kidney International
- Vol. 110 (4) , 1055-1057
Monitoring anti-nephrin antibodies in the management of recurrent diffuse podocytopathy
- 26 June 2026
- Published by Elsevier in Kidney International
- Vol. 110 (4) , 1055-1057
Monitoring anti-nephrin antibodies in the management of recurrent diffuse podocytopathy
- Open Access
- 31 December 2025
- Published by S. Karger AG in Glomerular Diseases
- Vol. 6 (1) , 26-35
The Cutting Edge: A Clinicopathology Minireview of Immunoglobulin A Nephropathy
Recent years have seen an explosion of interest in the pathogenesis and therapy of immunoglobulin A nephropathy (IgAN). Large cohort studies have facilitated improvements in disease classification and prognosis, including the establishment and validation of a standard pathological classification, the Oxford classification. Landmark treatment studies published in the past several years have solidified a basic therapeutic approach, emphasizing the value of adding immunomodulatory drugs to supportive care for aggressive disease. There are currently a large number of therapies with diverse mechanisms of action in active development for IgAN, promising at least to enhance our understanding of key pathogenic pathways and, at best, to eventually prove useful in slowing or stopping the progression of IgAN. In this cutting-edge feature, we use a clinical case to review and discuss the current standard of care in the diagnosis and treatment of IgAN, as well as to highlight emerging approaches to treatment.
- 31 December 2025
- Published by S. Karger AG in Glomerular Diseases
- Vol. 6 (1) , 26-35
Open AccessThe Cutting Edge: A Clinicopathology Minireview of Immunoglobulin A Nephropathy
Recent years have seen an explosion of interest in the pathogenesis and therapy of immunoglobulin A nephropathy (IgAN). Large cohort studies have facilitated improvements in disease classification and prognosis, including the establishment and validation of a standard pathological classification, the Oxford classification. Landmark treatment studies published in the past several years have solidified a basic therapeutic approach, emphasizing the value of adding immunomodulatory drugs to supportive care for aggressive disease. There are currently a large number of therapies with diverse mechanisms of action in active development for IgAN, promising at least to enhance our understanding of key pathogenic pathways and, at best, to eventually prove useful in slowing or stopping the progression of IgAN. In this cutting-edge feature, we use a clinical case to review and discuss the current standard of care in the diagnosis and treatment of IgAN, as well as to highlight emerging approaches to treatment.
- Open Access
- 9 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-2
Author Correction: Exome analysis links kidney malformations to developmental disorders and reveals causal genes
- 9 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-2
Open AccessAuthor Correction: Exome analysis links kidney malformations to developmental disorders and reveals causal genes
- Open Access
- 7 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
Exome analysis links kidney malformations to developmental disorders and reveals causal genes
Congenital anomalies of the kidneys and urinary tract (CAKUT) are developmental disorders that commonly cause pediatric chronic kidney disease and mortality. We examine here rare coding variants in 248 CAKUT trios and 1742 singleton CAKUT cases and compare them to 22,258 controls. Diagnostic and candidate diagnostic variants are detected in 14.1% of cases. We find a significant enrichment of rare damaging variants in constrained genes expressed during kidney development and in genes associated with other developmental disorders, suggesting phenotype expansion. Consistent with these data, 18% of CAKUT patients with diagnostic variants have neurodevelopmental or cardiac phenotypes. We identify 40 candidate genes, including CELSR1, SSBP2, XPO1, NR6A1, and ARID3A. Two are confirmed as CAKUT genes: ARID3A and NR6A1. This study suggests that many yet-unidentified syndromes would be discoverable with larger cohorts and cross-phenotype analysis, leading to clarification of the genetic and phenotypic spectrum of developmental disorders.
- 7 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
Open AccessExome analysis links kidney malformations to developmental disorders and reveals causal genes
Congenital anomalies of the kidneys and urinary tract (CAKUT) are developmental disorders that commonly cause pediatric chronic kidney disease and mortality. We examine here rare coding variants in 248 CAKUT trios and 1742 singleton CAKUT cases and compare them to 22,258 controls. Diagnostic and candidate diagnostic variants are detected in 14.1% of cases. We find a significant enrichment of rare damaging variants in constrained genes expressed during kidney development and in genes associated with other developmental disorders, suggesting phenotype expansion. Consistent with these data, 18% of CAKUT patients with diagnostic variants have neurodevelopmental or cardiac phenotypes. We identify 40 candidate genes, including CELSR1, SSBP2, XPO1, NR6A1, and ARID3A. Two are confirmed as CAKUT genes: ARID3A and NR6A1. This study suggests that many yet-unidentified syndromes would be discoverable with larger cohorts and cross-phenotype analysis, leading to clarification of the genetic and phenotypic spectrum of developmental disorders.
- 10 April 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (7) , 978-992
Proteinuria Trajectory and Disease Progression in Children and Adults with IgA Nephropathy/Vasculitis
Key Points: Defining risk of kidney function loss in IgA nephropathy and IgA vasculitis with nephritis is important for patient counseling and risk-based enrollment of clinical trials. Proteinuria trajectory over 2 years can uniquely identify patients at risk of loss of kidney function or kidney failure. Children and adults with the highest levels of proteinuria had a higher risk of progressive kidney disease compared with those with intermediate levels. Background: Identifying patients with IgA nephropathy at risk of disease progression is critical for clinical decision making, risk-based patient counseling, and optimal enrollment of clinical trials. Methods: Patients with IgA nephropathy and IgA vasculitis with nephritis were enrolled in the Cure Glomerulonephropathy Network, a multicenter observational cohort study. Children and adults were analyzed separately in four cohorts: (1) full, (2) incident, (3) prevalent, and (4) histology. Groups were defined using latent class trajectory modeling using proteinuria measurements over 2 years. Linear mixed models were used to calculate predicted eGFR slope. In adults, Cox proportional hazard models were used to model time to kidney failure or 40% eGFR decline as a function of the proteinuria trajectory group. Results: Of 919 patients with IgA nephropathy/IgA vasculitis with nephritis enrolled into the Cure Glomerulonephropathy Network, 368 adults and 234 children were included in the analysis. In the full adult cohort, group 1 had the lowest levels of proteinuria (interquartile range [IQR], 0.1–0.4 g/g), while groups 2 and 3 had intermediate and higher levels of proteinuria (IQR, 0.5–1.5 and IQR, 1.8–4.1 g/g), respectively. The average predicted time to eGFR 90, 16, and 8 years and >90, 67, and 11 years for proteinuria trajectory groups 1, 2, and 3 in the full adult and pediatric cohorts, respectively. In adults, adjusting for age, eGFR at enrollment, immunosuppression exposure, and hypertension, group 3 membership was associated with 3.13 (95% confidence interval [CI], 1.84 to 5.33), 1.98 (95% CI, 0.97 to 4.06), and 3.36 (95% CI, 1.59 to 7.13) times higher hazard of progressing to a composite outcome compared with group 2 membership in the full, prevalent, and histology cohorts, respectively, but not associated with progression in the incident cohort. Conclusions: Proteinuria trajectory is a major predictor of disease progression in patients with IgA nephropathy.
- 10 April 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (7) , 978-992
Proteinuria Trajectory and Disease Progression in Children and Adults with IgA Nephropathy/Vasculitis
Key Points: Defining risk of kidney function loss in IgA nephropathy and IgA vasculitis with nephritis is important for patient counseling and risk-based enrollment of clinical trials. Proteinuria trajectory over 2 years can uniquely identify patients at risk of loss of kidney function or kidney failure. Children and adults with the highest levels of proteinuria had a higher risk of progressive kidney disease compared with those with intermediate levels. Background: Identifying patients with IgA nephropathy at risk of disease progression is critical for clinical decision making, risk-based patient counseling, and optimal enrollment of clinical trials. Methods: Patients with IgA nephropathy and IgA vasculitis with nephritis were enrolled in the Cure Glomerulonephropathy Network, a multicenter observational cohort study. Children and adults were analyzed separately in four cohorts: (1) full, (2) incident, (3) prevalent, and (4) histology. Groups were defined using latent class trajectory modeling using proteinuria measurements over 2 years. Linear mixed models were used to calculate predicted eGFR slope. In adults, Cox proportional hazard models were used to model time to kidney failure or 40% eGFR decline as a function of the proteinuria trajectory group. Results: Of 919 patients with IgA nephropathy/IgA vasculitis with nephritis enrolled into the Cure Glomerulonephropathy Network, 368 adults and 234 children were included in the analysis. In the full adult cohort, group 1 had the lowest levels of proteinuria (interquartile range [IQR], 0.1–0.4 g/g), while groups 2 and 3 had intermediate and higher levels of proteinuria (IQR, 0.5–1.5 and IQR, 1.8–4.1 g/g), respectively. The average predicted time to eGFR 90, 16, and 8 years and >90, 67, and 11 years for proteinuria trajectory groups 1, 2, and 3 in the full adult and pediatric cohorts, respectively. In adults, adjusting for age, eGFR at enrollment, immunosuppression exposure, and hypertension, group 3 membership was associated with 3.13 (95% confidence interval [CI], 1.84 to 5.33), 1.98 (95% CI, 0.97 to 4.06), and 3.36 (95% CI, 1.59 to 7.13) times higher hazard of progressing to a composite outcome compared with group 2 membership in the full, prevalent, and histology cohorts, respectively, but not associated with progression in the incident cohort. Conclusions: Proteinuria trajectory is a major predictor of disease progression in patients with IgA nephropathy.
- 11 March 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (8) , 1561-1571
Family History in the Context of CKD
Key Points: Family history of kidney disease was not associated with kidney disease progression in the context of established CKD. Family history of diabetes was a risk factor of CKD progression independently of diabetes status, polygenic risk, and traditional risk factors. Background: A family history of health conditions may reflect shared genetic and/or environmental risk. It is not well known to what extent family history affects outcomes among patients with CKD. In this study, we investigated the associations of family history of CKD, diabetes, and other conditions with common comorbidities and kidney disease progression among patients with CKD. Methods: We performed an observational study of two prospective CKD cohorts, 2573 adults and children from the Cure Glomerulopathy Network and 3939 Chronic Renal Insufficiency Cohort adult participants. Self-reported first-degree family history of CKD, diabetes, and other common diseases was tested for associations with the risk of comorbidities and CKD progression using multivariable models. Results: Family history of common comorbid conditions was associated with higher risk of these conditions in the context of CKD, including approximately by over three-fold for diabetes (adjusted odds ratio [OR], 3.37; 95% confidence interval [CI], 2.73 to 4.15), 48% for cancer (adjusted OR, 1.48; 95% CI, 1.05 to 2.09), and 69% for cardiovascular disease (adjusted OR, 1.69; 95% CI, 1.36 to 2.10 in combined cohorts). While polygenic risk score (PRS) for CKD was associated with kidney disease progression (adjusted hazards ratio, 1.11; 95% CI, 1.06 to 1.16 in combined cohorts), family history of kidney disease was not an independent risk factor of disease progression in the context of existing CKD. By contrast, family history of diabetes was significantly associated with a higher risk of CKD progression independently of diabetes occurrence or PRS for diabetes (adjusted hazards ratio, 1.19; 95% CI, 1.05 to 1.35 in combined cohorts). Conclusions: Broad collection of family history in the context of CKD improved clinical risk stratification. Family history of diabetes was consistently associated with a higher risk of CKD progression independently of diabetes status or PRS for diabetes in both cohorts.
- 11 March 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (8) , 1561-1571
Family History in the Context of CKD
Key Points: Family history of kidney disease was not associated with kidney disease progression in the context of established CKD. Family history of diabetes was a risk factor of CKD progression independently of diabetes status, polygenic risk, and traditional risk factors. Background: A family history of health conditions may reflect shared genetic and/or environmental risk. It is not well known to what extent family history affects outcomes among patients with CKD. In this study, we investigated the associations of family history of CKD, diabetes, and other conditions with common comorbidities and kidney disease progression among patients with CKD. Methods: We performed an observational study of two prospective CKD cohorts, 2573 adults and children from the Cure Glomerulopathy Network and 3939 Chronic Renal Insufficiency Cohort adult participants. Self-reported first-degree family history of CKD, diabetes, and other common diseases was tested for associations with the risk of comorbidities and CKD progression using multivariable models. Results: Family history of common comorbid conditions was associated with higher risk of these conditions in the context of CKD, including approximately by over three-fold for diabetes (adjusted odds ratio [OR], 3.37; 95% confidence interval [CI], 2.73 to 4.15), 48% for cancer (adjusted OR, 1.48; 95% CI, 1.05 to 2.09), and 69% for cardiovascular disease (adjusted OR, 1.69; 95% CI, 1.36 to 2.10 in combined cohorts). While polygenic risk score (PRS) for CKD was associated with kidney disease progression (adjusted hazards ratio, 1.11; 95% CI, 1.06 to 1.16 in combined cohorts), family history of kidney disease was not an independent risk factor of disease progression in the context of existing CKD. By contrast, family history of diabetes was significantly associated with a higher risk of CKD progression independently of diabetes occurrence or PRS for diabetes (adjusted hazards ratio, 1.19; 95% CI, 1.05 to 1.35 in combined cohorts). Conclusions: Broad collection of family history in the context of CKD improved clinical risk stratification. Family history of diabetes was consistently associated with a higher risk of CKD progression independently of diabetes status or PRS for diabetes in both cohorts.
- 7 January 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (2) , 174-176
When a NeF Is Not Enough
- 7 January 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (2) , 174-176
When a NeF Is Not Enough
- Open Access
- 1 January 2025
- Published by S. Karger AG in Glomerular Diseases
- Vol. 5 (1) , 243-249
Familial Idiopathic Glomerular Disease due to a Unique Renal-Predominant Phenotype of MYH9-Related Disease: A Case Report
Introduction: MYH9-related disease (MYH9-RD) is a rare genetic cause of proteinuric kidney disease. It typically manifests as a syndromic condition, presenting with macrocytic thrombocytopenia, sensorineural hearing loss (SNHL), chronic glomerulopathy, elevated liver enzymes, and early-onset bilateral cataracts. In accordance with CARE guidelines, we present a case report of a father and daughter with renal-predominant MYH9-RD due to a recently described missense variant affecting the head domain of non-muscle myosin heavy chain IIA. Case Presentations: Patient 1 was an 18-year-old woman with childhood proteinuria who presented with severely advanced kidney failure. Dialysis was initiated as a bridge to a living unrelated renal transplant (LURT). Family history was notable for proteinuric kidney disease in her father (patient 2). Eight years later, genetic testing identified a likely pathogenic missense variant in the head domain of the MYH9 gene (c.1271G>A, p.R424Q). A predictive structural model was obtained via AlphaFold Protein Structure Database, in which the mutation interrupts hydrogen bonding and π-cation interactions, likely leading to protein misfolding. Subsequent clinical screening revealed persistent mild thrombocytopenia and elevated liver enzymes, without cataracts or SNHL. Patient 2 was a 53-year-old man with childhood proteinuria who eventually presented with stage 4 chronic kidney disease and soon after underwent LURT. After patient 1’s genetic diagnosis, he was confirmed to have the same mutation by genetic testing. Subsequent screening revealed mild thrombocytopenia and elevated liver enzymes with hepatic steatosis progressing to cirrhosis, without cataracts or SNHL. Conclusion: The finding of this MYH9 p.R424Q variant confirmed a diagnosis of MYH9-RD in these patients. MYH9 variants affecting the head domain typically result in severe thrombocytopenia. This recently reported head domain variant caused severe renal manifestations with mild thrombocytopenia and no manifestations of SNHL or cataracts in both patients, suggesting that this variant causes a renal-predominant form of MYH9-RD.
- 1 January 2025
- Published by S. Karger AG in Glomerular Diseases
- Vol. 5 (1) , 243-249
Open AccessFamilial Idiopathic Glomerular Disease due to a Unique Renal-Predominant Phenotype of MYH9-Related Disease: A Case Report
Introduction: MYH9-related disease (MYH9-RD) is a rare genetic cause of proteinuric kidney disease. It typically manifests as a syndromic condition, presenting with macrocytic thrombocytopenia, sensorineural hearing loss (SNHL), chronic glomerulopathy, elevated liver enzymes, and early-onset bilateral cataracts. In accordance with CARE guidelines, we present a case report of a father and daughter with renal-predominant MYH9-RD due to a recently described missense variant affecting the head domain of non-muscle myosin heavy chain IIA. Case Presentations: Patient 1 was an 18-year-old woman with childhood proteinuria who presented with severely advanced kidney failure. Dialysis was initiated as a bridge to a living unrelated renal transplant (LURT). Family history was notable for proteinuric kidney disease in her father (patient 2). Eight years later, genetic testing identified a likely pathogenic missense variant in the head domain of the MYH9 gene (c.1271G>A, p.R424Q). A predictive structural model was obtained via AlphaFold Protein Structure Database, in which the mutation interrupts hydrogen bonding and π-cation interactions, likely leading to protein misfolding. Subsequent clinical screening revealed persistent mild thrombocytopenia and elevated liver enzymes, without cataracts or SNHL. Patient 2 was a 53-year-old man with childhood proteinuria who eventually presented with stage 4 chronic kidney disease and soon after underwent LURT. After patient 1’s genetic diagnosis, he was confirmed to have the same mutation by genetic testing. Subsequent screening revealed mild thrombocytopenia and elevated liver enzymes with hepatic steatosis progressing to cirrhosis, without cataracts or SNHL. Conclusion: The finding of this MYH9 p.R424Q variant confirmed a diagnosis of MYH9-RD in these patients. MYH9 variants affecting the head domain typically result in severe thrombocytopenia. This recently reported head domain variant caused severe renal manifestations with mild thrombocytopenia and no manifestations of SNHL or cataracts in both patients, suggesting that this variant causes a renal-predominant form of MYH9-RD.